Psychedelic drug

PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA

Retrieved on: 
Tuesday, May 16, 2023
Psilocybin, GMP, Learning, CSE, Special access program, Research, SAP, Psychedelic drug, Joint venture, Shamanism, Capsule, Patient, Access, Health, Health Canada, MDMA, Pharmaceutical industry, MDXX

PharmAla has confirmed with Health Canada that this is the first-ever authorization of an MDMA-assisted therapy treatment under the Special Access Program.

Key Points: 
  • PharmAla has confirmed with Health Canada that this is the first-ever authorization of an MDMA-assisted therapy treatment under the Special Access Program.
  • Ultimately, that’s what all of our work should be about: improving lives for patients.” said Nick Kadysh, CEO of PharmAla.
  • Clinicians seeking to make a Special Access Program request for MDMA for their patients should submit a request directly to Health Canada’s Special Access Program.
  • Shaman Pharma will be distributing all Special Access Program requests for PharmAla.

Psychedelic Science 2023 Announces Sessions and Select Featured Speakers for the Therapy and Practitioners Tracks for June Conference

Retrieved on: 
Friday, May 12, 2023
Momentum, Therapy, LCSW, MGT, Norwegian Centre for Violence and Traumatic Stress Studies, Adolescence, Health equity, Trauma, Psychedelic drug, Doctor of Philosophy, LMFT, Multidisciplinary Association for Psychedelic Studies, MAPS, Icahn School of Medicine at Mount Sinai, Accreditation, CB1, Education, Research, Rivalry, Conference, Nightclub, Health care, Pharmaceutical industry, Nursing, Neuroscience, MD, Fireside, Psychiatry, Medicine

DENVER, May 12, 2023 (GLOBE NEWSWIRE) -- Today, Psychedelic Science 2023, the breakthrough psychedelic conference hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced its sessions and events covering the latest developments in therapy for psychedelic practitioners at this year’s conference taking place June 19-23, 2023 in Denver, Colorado.

Key Points: 
  • Additional Featured Speakers Include Dr. Julie Holland, Dr. Carl Hart and many more
    DENVER, May 12, 2023 (GLOBE NEWSWIRE) -- Today, Psychedelic Science 2023 , the breakthrough psychedelic conference hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced its sessions and events covering the latest developments in therapy for psychedelic practitioners at this year’s conference taking place June 19-23, 2023 in Denver, Colorado.
  • The Psychedelic Science 2023 Conference will feature 22 sessions and events covering advances in the potential therapeutic applications of psychedelics.
  • Conference attendees, including therapists, psychedelic practitioners, and other healthcare professionals, will have an opportunity to participate in a variety of sessions that address the potential application of psychedelic therapy, integration of post-psychedelic treatment experiences, and community-oriented and cultural competence in therapy practices.
  • PS2023 Featured Therapy and Practitioner Speakers include:
    Dr. Julie Holland, Psychiatrist, Author, Medical Advisor with The Rivals, MAPS, Palo Santo, Cardea, CB1, MGT, Fireside, Psychedelic Assembly, Apotheca Psychiatrist
    Dr. Rachel Yehuda, Vice-Chair and Professor of Psychiatry, Professor of Neuroscience, Director, Center for Psychedelic Psychotherapy and Trauma Research, Director, Traumatic Stress Studies division Icahn School of Medicine at Mount Sinai
    Danielle M. Herrera, MA, LMFT, Harm Reduction & Psychedelic Psychotherapist with Sage Integrative Health, Beckley Academy, Alchemy Community Therapy Center
    PS2023 Featured Therapy and Practitioner Sessions Include:
    Creating Standards of Care and Accreditation for Psychedelic Practitioners with Nicole T. Buchanan, Ph.D.
    Embedding Health Equity Principles into Psychedelic-Assisted Therapy and Education with Claudia Cuentes, LMFT, Sara Reed, MA, and Deran Young, LCSW
    Building Community-Oriented Therapy Practices with Pamela Kyskow, MD, Todd Haspect MEd, and Akua Brown, MD
    The State of Ketamine-Assisted Therapy with Raquel Bennett, PhD, Sunny Strasburg, LMFT, and Gita Vaid MD
    Considering Psychedelic Therapy for Adolescents with Corine de Boer, MD, Rebecca Kronman, LCSW, and Glauber Loures de Assis, PhD

Spotlight Media Corporation Discusses Launch of Bonfire Platform and Its Revenue Potential with The Stock Day Podcast

Retrieved on: 
Wednesday, May 10, 2023
OTC Markets Group, Cannabis, Psychedelic drug, Health, Interview, Collection, Bonfire, News, Movement, Music

"PSYC is a multimedia company focused on new and emerging market sectors, including psychedelics and cannabis," explained Flores.

Key Points: 
  • "PSYC is a multimedia company focused on new and emerging market sectors, including psychedelics and cannabis," explained Flores.
  • "Our flagship website, PsychedelicSpotlight.com , is a top-three media platform for the psychedelic sector, providing news, information, resources, and original content."
  • "Could you share with our listeners what Bonfire is and how it fits into your whole collection of media assets?"
  • "We have run preliminary revenue projections for Bonfire, and the potential of it is exciting," continued Flores.

PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health

Retrieved on: 
Monday, May 1, 2023
Psilocybin, Agreement, International joint venture, GMP, Intellectual property, CSE, Authorization, Marketing, VIT, ASX, IP, Psychedelic drug, Joint venture, Sale, JV, Patient, Letter, MDMA, Dietary supplement, Property management, Pharmaceutical industry

VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce the establishment of a 50:50 joint venture, "Cortexa", with Australian-based Vitura Health Limited (ASX: VIT) (“Vitura”). Following the execution of a letter of intent between Vitura and PharmAla in late February, the parties have executed definitive agreements (the "Agreements"), including for the establishment of an incorporated joint venture vehicle, Cortexa Pty Ltd ("Cortexa"), which is owned equally by Vitura and PharmAla, pursuant to the terms of a joint venture agreement (the "JV Agreement") entered into among Cortexa, Vitura and PharmAla.

Key Points: 
  • VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce the establishment of a 50:50 joint venture, "Cortexa", with Australian-based Vitura Health Limited (ASX: VIT) (“Vitura”).
  • Following the execution of a letter of intent between Vitura and PharmAla in late February, the parties have executed definitive agreements (the "Agreements"), including for the establishment of an incorporated joint venture vehicle, Cortexa Pty Ltd ("Cortexa"), which is owned equally by Vitura and PharmAla, pursuant to the terms of a joint venture agreement (the "JV Agreement") entered into among Cortexa, Vitura and PharmAla.
  • Cortexa is an Australian company, jointly owned by Vitura and PharmAla and with equal board representation.
  • In announcing the Joint Venture, Nick Kadysh, CEO of PharmAla Biotech, said:
    “In seeking a partner to be the market leading supplier of GMP manufactured MDMA and Psilocybin in Australia, we looked far and wide.

Psychedelic Science Announces Sessions and Select Featured Speakers for Science and Research Tracks for 2023 Conference

Retrieved on: 
Thursday, April 27, 2023
Momentum, Psilocybin, Science, Drug discovery, Safety, Efficacy, Cognition, Psychedelic drug, Aerospace Education Services Project, Multidisciplinary Association for Psychedelic Studies, Breakthrough therapy, Cancer, LCPC, MAPS, Diving, Medial, Research, Therapy, Conference, Breakthrough, PTSD, Nightclub, Pharmaceutical industry, Tutoring, Patient

DENVER, April 27, 2023 (GLOBE NEWSWIRE) -- Today, Psychedelic Science 2023, the breakthrough psychedelic conference hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced its sessions and events diving into the latest developments in the science and clinical research of psychedelics at this year’s conference taking place June 19-23, 2023 in Denver, Colorado.

Key Points: 
  • DENVER, April 27, 2023 (GLOBE NEWSWIRE) -- Today, Psychedelic Science 2023 , the breakthrough psychedelic conference hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced its sessions and events diving into the latest developments in the science and clinical research of psychedelics at this year’s conference taking place June 19-23, 2023 in Denver, Colorado.
  • The Psychedelic Science 2023 Conference will feature 38 sessions and events covering the scientific research driving the public conversation and acceptance of psychedelic science in modern medicine.
  • More information about Psychedelic Science 2023 programming in sessions, formats, and themes can be found here .
  • PS 2023 Featured Science and Research Speakers include:
    Dr. Darron Smith, Scholar, Researcher, and Author with Medial & Education Services, LLC
    PS 2023 Featured Science and Research Sessions Include:
    The Safety and Efficacy of Psilocybin Therapy in Patients with Cancer and Major Depressive Disorder with Manish Agrawal, M.D.

Psychedelic Drugs Global Market Report 2023: Sector to Reach $5.7 Billion by 2027 at a 7.5% CAGR - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 27, 2023
Alternative Medicine, Pharmaceutical, Health, Depression, Opioid, GHB, Anxiety, Narcolepsy, Intelligence, Pfizer, Research, Psychedelic drug, Row, Ketamine, Post-traumatic stress disorder, Addiction, Ecosystem, Environment, Pharmaceutical industry, Drug, Fine chemical

The global market for psychedelic drugs reached $3.7 billion in 2021.

Key Points: 
  • The global market for psychedelic drugs reached $3.7 billion in 2021.
  • This market is projected to grow at a compound annual growth rate (CAGR) of 7.5% and reach $5.7 billion by the end of 2027.
  • Growing scientific support for the benefits of psychedelic drugs, regulatory advancements supporting the development of psychedelic drugs, and increasing patient and physician acceptance of these drugs are key growth drivers of the market.
  • In 2021 the North American market for psychedelic drugs was valued at $1.5 billion, representing approximately 41.5% of the global market.

PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin

Retrieved on: 
Tuesday, April 25, 2023
Psilocybin, GMP, COPD, Concussion, Asthma, Bronchitis, TBI, OSA, Inflammatory bowel disease, Pain, Addiction, Patient, Traumatic brain injury, Psychedelic drug, Anxiety, Rheumatoid arthritis, Pharmaceutical industry

VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (MDMA.CSE) is excited to have received a signed purchase order for GMP LaNeo MDMA and Psilocybin by Incannex (IHL.ASX), a NASDAQ-listed psychedelic research company and clinic operator based in Australia.

Key Points: 
  • VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (MDMA.CSE) is excited to have received a signed purchase order for GMP LaNeo MDMA and Psilocybin by Incannex (IHL.ASX), a NASDAQ-listed psychedelic research company and clinic operator based in Australia.
  • “A significant number of companies have come to a similar conclusion: only PharmAla Biotech can be trusted to ensure a safe, predictable and regulatory-compliant drug supply for patients in the nascent australian medical Psychedelics market,” said Nick Kadysh, PharmAla’s CEO.
  • PharmAla is the first publicly-traded company to manufacture GMP MDMA, and the first company to make available to researchers two GMP Psychedelic APIs.
  • Incannex intends to take possession of their order as soon as permitted by regulatory timelines.

PharmAla Biotech to supply Clinical Psychedelic Lab at Monash University Clinical Trial with LaNeo MDMA

Retrieved on: 
Thursday, April 20, 2023
Monash University, GMP, Therapy, Research, Clinical trial, MDMA, Pharmaceutical industry, Psychedelic drug

VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for the Clinical Psychedelic Lab at Monash University’s upcoming Phase 2 Clinical Trial.

Key Points: 
  • VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for the Clinical Psychedelic Lab at Monash University’s upcoming Phase 2 Clinical Trial.
  • “With this supply agreement, PharmAla continues to establish itself as the premier supplier of choice for clinical MDMA researchers in Australia and globally.
  • This is the fourth major Clinical Trial to select PharmAla as their MDMA supplier in Australia.
  • PharmAla is the first publicly-traded company to manufacture GMP MDMA, and the first company to make available to researchers two GMP Psychedelic APIs.

Veterans Exploring Treatment Solutions (VETS) Applauds Bipartisan Push to Include Active Duty Military Members in Psychedelic-Assisted Therapy Research

Retrieved on: 
Thursday, April 13, 2023
Psilocybin, Letter, Psychedelic treatments for trauma-related disorders, Depression, Suicide, Woman, Research, Ibogaine, TBI, Psychedelic drug, Bangladesh Technical Education Board, Moral injury, SAN, Hand, Mental health, Bipartisanship, NIH, Social media, PTSD, Crenshaw, Pharmaceutical industry, Veteran

As a nonprofit organization that supports veterans in accessing psychedelic-assisted therapies, VETS recognizes the critical importance of including active duty servicemembers in psychedelic research.

Key Points: 
  • As a nonprofit organization that supports veterans in accessing psychedelic-assisted therapies, VETS recognizes the critical importance of including active duty servicemembers in psychedelic research.
  • The recent Phase 3 Trial of MDMA-Assisted Therapy for PTSD demonstrated the significant impact of psychedelic treatment on individuals suffering from trauma-related disorders.
  • Other compounds, like psilocybin and ibogaine, are also showing incredible promise in addressing these issues– but more research is critically needed.
  • Our active duty service men and women deserve to be included in NIH-funded psychedelic research.

PSYC Set to Relaunch Bonfire with “Psychedelics for Beginners” Online Course

Retrieved on: 
Wednesday, April 12, 2023
Online, OTC Markets Group, Multimedia, Psychedelic drug, Management, Growth, Safety, Video game, Nightclub, Bonfire

Current plans are to utilize this initial 30-day course as the basis for additional courses that will be developed and ultimately become the centerpiece of the Bonfire community.

Key Points: 
  • Current plans are to utilize this initial 30-day course as the basis for additional courses that will be developed and ultimately become the centerpiece of the Bonfire community.
  • “The redevelopment and relaunch of Bonfire is certainly something that is a long time coming for us,” said PSYC CEO, David Flores.
  • Bonfire has a unique opportunity to become a highly attractive gateway to tried and true self-help and healing, such as psychedelic integration.
  • For anyone interested in joining Bonfire’s “Psychedelics for Beginners” Free Online Course, please visit the Bonfire Community page on Psychedelic Spotlight to sign up.